Commenting on the data, Luis-Felipe Graterol, Medical Director, Bayer HealthCare said, ‘It is encouraging to see that the efficacy seen in the clinical trials for Eylea is being reflected in clinical practice and that patients are benefitting from this treatment across the country. The continued enthusiasm to investigate Eylea’s use in the clinical setting will work towards increasing the wealth of knowledge about this treatment.’
In one poster presented at the conference, data from a one year, retrospective, study showed EYLEA to be effective in patients with wAMD who were resistant to previous treatment with ranibizumab. All 10 patients (10 eyes) within the study had at least seven previous injections of ranibizumab, with the mean number of previous injections being 13.9 (range 7-29). Visual acuity (VA) and central retinal thickness (CRT) was measured at the time of switching and four months after the first EYLEA injection. The mean VA before switching and at four months was 0.68 LogMAR (range: 0.42-1.04) and 0.59 LogMAR (range: 0.06-0.90) respectively; with an improvement in VA seen in 70% (7/10) of eyes, a deterioration in 20% (2/10) and stabilisation in 10% (1/10). The mean central foveal thickness (CRT) before switching and at four months was 396.9µm (range: 293-602) and 321.8µm (range: 220-523) respectively; with a decrease in 80% (8/10) of eyes, increase in 10% (1/10) and stabilisation (within 5µm) in 10% (1/10).
Another poster was data from a prospective case-series study that showed that EYLEA produced an immediate anatomical response in 17 wAMD patients resistant to ranibizumab injections. Injection history, best corrected visual acuity (BCVA) and CRT were measured at every visit. Results showed that after one injection of EYLEA the CFT average was 324.32µm (range 222-585), after four months (three consecutive injections) the CFT average was 294.76µm (range 184-640) and after six months the CFT average was 356µm (range 206-609). At the fifth visit, 47% (8/17) of patients required repeated injection either for persistent fluid or for recurrence. At the sixth and final visit 23.5% (4/17) needed repeated injections. BCVA at the beginning of the study was an average of 0.998, at month one the average was 1.01, at month four (after three consecutive injections) the average was 0.952 and at month six it was 0.933. The anatomical improvement did not correlate with functional improvement in all patients; this was anticipated due to damage observed before initiation of EYLEA treatment. Based on these results, there is a recommendation for early intervention when faced with resistance to ranibizumab to avoid irreversible damage of the foveal area.
The third poster highlighted that EYLEA can deliver favourable outcomes in the clinical setting in both treatment-naïve and pre-treated patients. Of the 28 patients (30 eyes) included in the study, 30% had previous ranibizumab injections. Results showed that three months after the first EYLEA injection 76.7% (23/30) of eyes had gained >5 letters, with 23.3% losing >5 letters (7/30). CRT decreased in 80% of eyes, with a mean reduction of 137µm (range: 1-332), and increased in 20% of eyes, with a mean thickening of 114µm (range: 54-188). There was no statistically significant difference in the change in VA and CRT between the treatment-naïve and pre-treated eyes.